GE HealthCare is collaborating with Novo Nordisk to further advance the clinical and product development of peripheral-focused ultrasound (PFUS) to treat type 2 diabetes and obesity.
PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease. Previous reports suggest that it could impact glucose metabolism in people with diabetes through personalized ultrasound stimulation of nerve pathways.
As part of the collaboration, GE HealthCare and Novo Nordisk will combine their respective expertise in ultrasound medical technology and metabolic disease treatment and management. The two companies will work together to develop a PFUS solution to improve patient care, building upon the foundational research performed by the GE HealthCare team. Additional terms of the agreement were not disclosed.